Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments

Alessandro Franchi, Duccio Rossi Degli Innocenti, Annarita Palomba, Lucia Miligi, Fabiola Paiar, Ciro Franzese, Marco Santucci

Research output: Contribution to journalArticlepeer-review

Abstract

We have previously shown that a subset of sinonasal intestinal-type adenocarcinomas (ITAC) shows activation of the epidermal growth factor-receptor (EGFR) pathway. In this study we examine the status of the EGFR, KRAS and BRAF genes in a series of sinonasal intestinal (ITAC) and non-intestinal type adenocarcinomas (non-ITAC). Eighteen ITACs and 12 non-ITACs were studied immunohistochemically for EGFR expression. Point mutations were analyzed for EGFR exons 19 and 21, KRAS exon 2 and BRAF exon 15 by direct sequencing. Non-ITACs showed significantly higher expression of EGFR (p = 0.015). Mutation analysis revealed one ITAC with EGFR and one ITAC with KRAS mutation, while two non-ITACs presented mutation of BRAF. We conclude that a subset of sinonasal adenocarcinomas shows overexpression of EGFR, while activating mutations of the signaling cascade downstream of EGFR are rare, suggesting that these tumors could be good candidates for anti-EGFR therapies.

Original languageEnglish
Pages (from-to)571-579
Number of pages9
JournalPathology and Oncology Research
Volume20
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • BRAF
  • EGFR
  • Intestinal type adenocarcinoma
  • KRAS
  • Sinonasal adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments'. Together they form a unique fingerprint.

Cite this